Clinical application of Sugammadex

WANG Yun; CAO Yong-bing; JIANG Yuan-ying; YAN Tian-hua

doi:10.3969/j.issn.1006-0111.2012.06.002

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 30 Issue 6

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2012 > 30(6): 405-407,453

WANG Yun, CAO Yong-bing, JIANG Yuan-ying, YAN Tian-hua. Clinical application of Sugammadex[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(6): 405-407,453. doi: 10.3969/j.issn.1006-0111.2012.06.002

Citation:

WANG Yun, CAO Yong-bing, JIANG Yuan-ying, YAN Tian-hua. Clinical application of Sugammadex[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(6): 405-407,453. doi: 10.3969/j.issn.1006-0111.2012.06.002

Clinical application of Sugammadex

doi: 10.3969/j.issn.1006-0111.2012.06.002

1.
Department of physiology, China Pharmaceutical University, Nanjing 210009, China
2.
School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2012-03-14
Rev Recd Date: 2012-05-02

Abstract

Sugammadex had been licensed for reversal of rocuronium and vecuronium induced neuromuscular blockade in Europe since 2008, which had shown to be efficacious and had a good safety profile so far. The potential for Sugammadex to change the management of NMB, in routine clinical practice, in emergency situations and in special populations were reviewed in this paper.
- neuromuscular blockade reversal,
- sugammadex,
- rocuronium,
- suxamethonium,
- neostigmine

References

[1]	Aniskevich S, Leone BJ, Brull SJ. Sugammadex:a novel approach to reversal of neuromuscular blockade[J]. Expert Rev Neurother, 2011,11(2):185.
[2]	Lee C. Goodbye suxamethonium[J]. Anaesthesia, 2009,64(Suppl. 1):73.
[3]	Schultz P, Ibsen M, φstergaard D, et al. Onset and duration of action of rocuronium-from tracheal intubation, through intense block to complete recovery[J]. Acta Anaesthesiol Scand, 2001,45(5):612.
[4]	Kopman AF, Zhaku B, Lai KS. The "intubating dose" of succinylcholine:the effect of decreasing doses on recovery time[J]. Anesthesiology, 2003,99(5):1050.
[5]	Perry JJ, Lee JS, Sillberg VA, et al. Rocuronium versus succinylcholine for rapid sequence induction intubation[J]. Cochrane Database Syst Rev, 2008,2:CD002788.
[6]	McTernan CN, Rapeport DA, Ledowski T. Successful use of rocuronium and sugammadex in an anticipated difficult airway scenario[J]. Anaesth Intensive Care,2010,38(2):390.
[7]	闻大翔,欧阳葆怡,杭燕南. 肌肉松弛药[M]. 上海:世界图书出版公司,2007:1.
[8]	Jones RK, Caldwell JE, Brull SJ, et al. Reversal of profound rocuronium induced blockade with sugammadex:a randomized comparison with neostigmine[J].Anesthesiology,2008, 109(5):816.
[9]	Plaud B, Debaene B, Donati F, et al. Residual paralysis after emergence from anesthesia[J]. Anesthesiology, 2010,112(4):1013.
[10]	McDonnell NJ, Pavy TJ, Green LK. Sugammadex in the management of rocuronium-induced anaphylaxis[J]. Br J Anaesth, 2011,106(2):199.
[11]	Plaud B, Meretoja O, Hofmockel R, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients[J]. Anesthesiology, 2009, 110(2):284.
[12]	Suzuki T, Kitajima O, Ueda K, et al. Reversibility of rocuronium-induced profound neuromuscular block with sugammadex in younger and older patients[J]. Br J Anaesth, 2011,106(6):823.
[13]	Monk T. Obesity has no clinically relevant impact upon recovery time following administration of sugammadex[C]. Presented at Annual Meeting of American Society of Anesthesiologists. Orlando:2008. Abstract A682.
[14]	Desforges JC, McDonnell NJ. Sugammadex in the management of a failed intubation in a morbidly obese patient[J]. Anaesth Intensive Care, 2011,39(4):763.
[15]	Van Lancker P, Dillemans B, Bogaert T, et al. Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients[J]. Anaesthesia, 2011,66(8):721.
[16]	Sharp LM, Levy DM. Rapid sequence induction in obstetrics revisited[J]. Curr Opin Anaesthesiol, 2009,22(3):357
[17]	Puhringer FK, Kristen P, Rex C. Sugammadex reversal of rocuronium-induced neuromuscular block in Caesarean section patients:a series of seven cases[J]. Br J Anaesth, 2010, 105(5):657.
[18]	Williamson RM, Mallaiah S, Barclay P. Rocuronium and sugammadex for rapid sequence induction of obstetric general anaesthesia[J]. Acta Anaesthesiol Scand, 2011, 55:694.
[19]	Robertson EN, Driessen JJ, Booij LH. Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal failure[J]. Eur J Anaesthesiol, 2005,22(1):4.
[20]	Yentis SM. Suxamethonium and hyperkalaemia[J]. Anaesth Intensive Care, 1990, 18(1):92.
[21]	Staals LM, Snoeck MM, Driessen JJ, et al. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function[J]. Br J Anaesth, 2008,101(4):492.
[22]	Porter MV, Paleologos MS. The use of rocuronium in a patient with cystic fibrosis and end-stage lung disease made safe by sugammadex reversal[J]. Anaesth Intensive Care, 2011, 39(2):299.
[23]	Unterbuchner C, Fink H, Blobner M. The use of sugammadex in a patient with myasthenia gravis[J]. Anaesthesia, 2010, 65(3):302.
[24]	Matsuki Y, Hirose M, Tabata M, et al. The use of sugammadex in a patient with myotonic dystrophy[J].Eur J Anaesthesiol,2010,28(2):145.
[25]	de Boer HD, van Esmond J, Booij LH, et al. Reversal of rocuronium induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy[J]. Paediatr Anaesth, 2009, 19(12):1226
[26]	Cammu G, De Kam PJ, Demeyer I, et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers[J]. Br J Anaesth, 2008, 100(3):373
[27]	de Kam PJ, van Kuijk J, Prohn M, et al. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuroniumor vecuroniumon QTc prolongation:a thorough QTc study[J]. Clin Drug Investig, 2010, 30(9):599.
[28]	Peeters PA, Michiel W,Heuvel VD, et al. Safety, tolerability and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects:a randomized,double-blind, crossover, placebo-controlled, single-centre study[J]. Clin Drug Investig, 2010, 30(12):867.
[29]	Menendez-Ozcoidi L, Ortiz-Gómez JR. Olaguibel-Ribero JM, et al. Allergy to low dose sugammadex[J]. Anaesthesia, 2011, 66(3), 217.
[30]	Paton F, Paulden M, Chambers D, et al. Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block:a systematic review and economic evaluation[J]. Br J Anaesth, 2010, 105(5):558.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(8109) PDF downloads(2774) Cited by()

Proportional views

Clinical application of Sugammadex

1. Department of physiology, China Pharmaceutical University, Nanjing 210009, China

2. School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2012-03-14

Rev Recd Date: 2012-05-02

Key words:

Abstract: Sugammadex had been licensed for reversal of rocuronium and vecuronium induced neuromuscular blockade in Europe since 2008, which had shown to be efficacious and had a good safety profile so far. The potential for Sugammadex to change the management of NMB, in routine clinical practice, in emergency situations and in special populations were reviewed in this paper.

HTML

Reference (30)

[1]	Aniskevich S, Leone BJ, Brull SJ. Sugammadex:a novel approach to reversal of neuromuscular blockade[J]. Expert Rev Neurother, 2011,11(2):185.
[2]	Lee C. Goodbye suxamethonium[J]. Anaesthesia, 2009,64(Suppl. 1):73.
[3]	Schultz P, Ibsen M, φstergaard D, et al. Onset and duration of action of rocuronium-from tracheal intubation, through intense block to complete recovery[J]. Acta Anaesthesiol Scand, 2001,45(5):612.
[4]	Kopman AF, Zhaku B, Lai KS. The "intubating dose" of succinylcholine:the effect of decreasing doses on recovery time[J]. Anesthesiology, 2003,99(5):1050.
[5]	Perry JJ, Lee JS, Sillberg VA, et al. Rocuronium versus succinylcholine for rapid sequence induction intubation[J]. Cochrane Database Syst Rev, 2008,2:CD002788.
[6]	McTernan CN, Rapeport DA, Ledowski T. Successful use of rocuronium and sugammadex in an anticipated difficult airway scenario[J]. Anaesth Intensive Care,2010,38(2):390.
[7]	闻大翔,欧阳葆怡,杭燕南. 肌肉松弛药[M]. 上海:世界图书出版公司,2007:1.
[8]	Jones RK, Caldwell JE, Brull SJ, et al. Reversal of profound rocuronium induced blockade with sugammadex:a randomized comparison with neostigmine[J].Anesthesiology,2008, 109(5):816.
[9]	Plaud B, Debaene B, Donati F, et al. Residual paralysis after emergence from anesthesia[J]. Anesthesiology, 2010,112(4):1013.
[10]	McDonnell NJ, Pavy TJ, Green LK. Sugammadex in the management of rocuronium-induced anaphylaxis[J]. Br J Anaesth, 2011,106(2):199.
[11]	Plaud B, Meretoja O, Hofmockel R, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients[J]. Anesthesiology, 2009, 110(2):284.
[12]	Suzuki T, Kitajima O, Ueda K, et al. Reversibility of rocuronium-induced profound neuromuscular block with sugammadex in younger and older patients[J]. Br J Anaesth, 2011,106(6):823.
[13]	Monk T. Obesity has no clinically relevant impact upon recovery time following administration of sugammadex[C]. Presented at Annual Meeting of American Society of Anesthesiologists. Orlando:2008. Abstract A682.
[14]	Desforges JC, McDonnell NJ. Sugammadex in the management of a failed intubation in a morbidly obese patient[J]. Anaesth Intensive Care, 2011,39(4):763.
[15]	Van Lancker P, Dillemans B, Bogaert T, et al. Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients[J]. Anaesthesia, 2011,66(8):721.
[16]	Sharp LM, Levy DM. Rapid sequence induction in obstetrics revisited[J]. Curr Opin Anaesthesiol, 2009,22(3):357
[17]	Puhringer FK, Kristen P, Rex C. Sugammadex reversal of rocuronium-induced neuromuscular block in Caesarean section patients:a series of seven cases[J]. Br J Anaesth, 2010, 105(5):657.
[18]	Williamson RM, Mallaiah S, Barclay P. Rocuronium and sugammadex for rapid sequence induction of obstetric general anaesthesia[J]. Acta Anaesthesiol Scand, 2011, 55:694.
[19]	Robertson EN, Driessen JJ, Booij LH. Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal failure[J]. Eur J Anaesthesiol, 2005,22(1):4.
[20]	Yentis SM. Suxamethonium and hyperkalaemia[J]. Anaesth Intensive Care, 1990, 18(1):92.
[21]	Staals LM, Snoeck MM, Driessen JJ, et al. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function[J]. Br J Anaesth, 2008,101(4):492.
[22]	Porter MV, Paleologos MS. The use of rocuronium in a patient with cystic fibrosis and end-stage lung disease made safe by sugammadex reversal[J]. Anaesth Intensive Care, 2011, 39(2):299.
[23]	Unterbuchner C, Fink H, Blobner M. The use of sugammadex in a patient with myasthenia gravis[J]. Anaesthesia, 2010, 65(3):302.
[24]	Matsuki Y, Hirose M, Tabata M, et al. The use of sugammadex in a patient with myotonic dystrophy[J].Eur J Anaesthesiol,2010,28(2):145.
[25]	de Boer HD, van Esmond J, Booij LH, et al. Reversal of rocuronium induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy[J]. Paediatr Anaesth, 2009, 19(12):1226
[26]	Cammu G, De Kam PJ, Demeyer I, et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers[J]. Br J Anaesth, 2008, 100(3):373
[27]	de Kam PJ, van Kuijk J, Prohn M, et al. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuroniumor vecuroniumon QTc prolongation:a thorough QTc study[J]. Clin Drug Investig, 2010, 30(9):599.
[28]	Peeters PA, Michiel W,Heuvel VD, et al. Safety, tolerability and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects:a randomized,double-blind, crossover, placebo-controlled, single-centre study[J]. Clin Drug Investig, 2010, 30(12):867.
[29]	Menendez-Ozcoidi L, Ortiz-Gómez JR. Olaguibel-Ribero JM, et al. Allergy to low dose sugammadex[J]. Anaesthesia, 2011, 66(3), 217.
[30]	Paton F, Paulden M, Chambers D, et al. Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block:a systematic review and economic evaluation[J]. Br J Anaesth, 2010, 105(5):558.

Message Board

Clinical application of Sugammadex

doi: 10.3969/j.issn.1006-0111.2012.06.002

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views